摘要
Background:To compare the treatment effectiveness and safety among transarterial infusion chemotherapy(TAI)with FOLFOX regimen,transarterial chemoembolization(TACE),and sorafenib in patients with BCLC stage C hepatocellular carcinoma(HCC).Methods:The data of consecutive patients with BCLC stage C HCC treated with TAI,TACE,or sorafenib from January 2015 to December 2018 at three centers were retrospectively analyzed.Propensity-score matched(PSM)analysis was pairwise performed to reduce selection bias.Treatment effectiveness and safety were evaluated and compared using the Kaplan-Meier method,log-rank test,Cox regression models,andχ2 test.Results:The median overall survival(OS)in the matched TAI cohort was significantly longer than the sorafenib cohort(19.6 vs.7.5 months,P=0.009),and the TACE cohort(estimated 27.8 vs.6.6 months,P<0.001).The difference in median progression-free survival(PFS)between the matched TAI and sorafenib cohorts was not significant(5.8 vs.2.3 months,P=0.219).The median PFS in the matched TAI cohort was significantly longer than the TACE cohort(6.5 vs.2.8 months,P<0.001).The objective response rate(ORR)in the matched TAI cohort was significantly higher than the sorafenib cohort(36.4%vs.0.0%,P<0.001)and the TACE cohort(48.7%vs.4.7%,P<0.001).The incidences of adverse events(AEs)were similar among these three cohorts.Conclusions:TAI with FOLFOX regimen was an effective and safe therapy that improved survival of patients with BCLC stage C HCC.
基金
This study was supported by the National Natural Science Foundation of China(No.81871985)
Natural Science Foundation of Guangdong Province(No.2018A0303130098 and No.2017A030310203)
Science and Technology Planning Project of Guangdong Province(No.2017A020215112)
Medical Scientific Research Foundation of Guangdong Province(No.A2017477)
Science and Technology Planning Project of Guangzhou(No.201903010017 and No.201904010479)
Clinical Trials Project(5010 Project)of Sun Yat-sen University(No.5010-2017009)
and Clinical Trials Project(308 Project)of Sun Yat-sen University Cancer Center(No.308-2015-014).
作者简介
Correspondence to:Rongping Guo.Sun Yat-sen University Cancer Center,651 Dongfeng East Road,Guangzhou 510000,China.Email:guorp@sysucc.org.cn。
